Psychiatry

Researchers find an increased risk of offspring ADHD symptoms due to maternal anxiety.

Researchers found a significant association between polygenic risk scores for ADHD and reaction time variability, but not commission errors.

Recent clinical trials have shown positive topline results for SPN-812.

A conversation around how burnout, COVID-19, politicization, and career progression programs influence the state of the largest US healthcare team.

National survey data suggest that, well before COVID-19, the largest healthcare workforce in the US has been challenged by understaffing and stressful situations.

A higher percentage of patients suffering from a severe mental disorder such as schizophrenia or bipolar disorder, died from a COVID-19 infection than the control group.

Data shows that nurses and midwives are likely the preferred non-specialist providers to offer perinatal interventions.

Suicide rates in 2020 have increased most in individuals younger than 30 years old.

A longtime psychiatrist writes on a doctor's propensity for irritation, anxiety and self-medicating, and the work that goes into caring for colleagues.

Dr. Cortese explains how more data could improve ADHD care.

Dr. Cortese discusses the current gaps in ADHD treatment.

Women, younger individuals, and those living in rural areas were more likely to suffer from anxiety due to the COVID-19 pandemic.

Individuals diagnosed with mood or anxiety disorders were not linked to higher COVID-19 mortality.

New study will look at psychedelics as a treatment for PTSD.

These findings underscore the importance of safely implementing new marijuana legislation across the US.

Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.

A high fasting insulin level trajectory was associated with psychosis, while puberty-onset BMI increase was linked to depression.

CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.

Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.

The role of many in psychiatry has changed during the COVID-19 pandemic.

Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.

Personalized, daily self-reporting for patients could influence future therapeutic strategies.

Randomized controlled trials are needed to evaluate their efficacy in comparison with in-person group meetings.

Investigators have observed a development-related shift in risks from teenaged ADHD and alcohol use risks in the patients' 30s.

A pair of researchers present plans to improve collaboration with other professionals in ADHD.